- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02392078
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN)
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Laura Menck
- Email: lmenck@monteris.com
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- University of British Columbia
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Barrow Neurological Institute at Dignity Health St. Joseph's Hospital & Medical Center
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
La Jolla, California, United States, 92093
- University of California, San Diego
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University School Of Medicine
-
-
Florida
-
Orlando, Florida, United States, 32804
- Advent Health Orlando
-
Saint Petersburg, Florida, United States, 33701
- Johns Hopkins All Children's Hospital
-
Weston, Florida, United States, 33331
- The Cleveland Clinic Florida
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40241
- Norton Cancer Institute
-
Louisville, Kentucky, United States, 40208
- University of Louisville
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
Saint Paul, Minnesota, United States, 55102
- United Children's Hospital St. Paul
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
New York, New York, United States, 10016
- New York University Langone Medical Center
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Danville, Pennsylvania, United States, 17822
- Geisinger Medical Center
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37205
- Saint Thomas West Hospital and Research Institute
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Houston, Texas, United States, 77030
- MD Anderson
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject or legally authorized representative provides written authorization and/or consent
- Subject who is to undergo thermal therapy by the NeuroBlate® System for treatment of their neurological disorder
Exclusion Criteria:
- Subject who is, or is expected to be inaccessible for follow-up
- Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the investigator, may prevent participation or otherwise render subject ineligibility for the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (Reportable adverse events)
Time Frame: up to 12 months
|
Safety profile described by the NBS and surgical-related AEs
|
up to 12 months
|
Reason for NeuroBlate
Time Frame: Index procedure
|
To identify the primary reason the NeuroBlate system was chosen for subject
|
Index procedure
|
Number of patients demonstrating local control, overall survival, and seizure freedom (ENGEL and ILAE classifications)
Time Frame: up to 12 months or last follow-up
|
Collected for all subjects by disease etiology. Local control as measured by time to local tumor recurrence. Overall survival assessed by Kaplan-Meier method. Seizure freedom assessed for all subjects with epilepsy at time of last follow-up. The ENGEL surgical outcome scale is composed of four classes of epilepsy (Class I, Class II, Class III, Class IV) categorized by severity. The ILAE outcome scale contains six classes (Class 1, 2, 3, 4, 5, 6) categorized by severity. |
up to 12 months or last follow-up
|
Change in Quality of Life
Time Frame: up to 12 months or last follow-up
|
Assessed by the following questionnaires:
|
up to 12 months or last follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eric Leuthardt, MD, Washington University School of Medicine
Publications and helpful links
General Publications
- Landazuri P, Shih J, Leuthardt E, Ben-Haim S, Neimat J, Tovar-Spinoza Z, Chiang V, Spencer D, Sun D, Fecci P, Baumgartner J. A prospective multicenter study of laser ablation for drug resistant epilepsy - One year outcomes. Epilepsy Res. 2020 Nov;167:106473. doi: 10.1016/j.eplepsyres.2020.106473. Epub 2020 Sep 22.
- Kim AH, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, Chiang V, Smith K, Williams BJ, Mohammadi AM, Judy K, Sloan A, Tovar-Spinoza Z, Baumgartner J, Hadjipanayis C, Leuthardt EC. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery. 2020 Sep 1;87(3):E338-E346. doi: 10.1093/neuros/nyaa071.
- Rennert RC, Khan U, Bartek J, Tatter SB, Field M, Toyota B, Fecci PE, Judy K, Mohammadi AM, Landazuri P, Sloan AE, Kim AH, Leuthardt EC, Chen CC. Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization. Neurosurgery. 2020 Apr 1;86(4):538-547. doi: 10.1093/neuros/nyz141.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LAANTERN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Movement Disorders
-
HaEmek Medical Center, IsraelCompletedEyelid Movement Disorders
-
University of ZurichCompleted
-
Joseph JankovicNo longer availableHyperkinetic Movement Disorders
-
University of Southern CaliforniaCompletedMovement Disorders in Children
-
The Cleveland ClinicActive, not recruitingFunctional Movement DisorderUnited States
-
National Institute of Neurological Disorders and...RecruitingFunctional Movement DisorderUnited States
-
University of AmericasActive, not recruitingFragility | Functional Movement DisorderChile
-
National Institute of Neurological Disorders and...CompletedMovement DisorderUnited States
-
Universita di VeronaNot yet recruiting
-
National Institute of Neurological Disorders and...Completed
Clinical Trials on NeuroBlate System
-
Monteris MedicalTerminated
-
Monteris MedicalCompleted
-
Monteris MedicalCompletedPrimary Brain TumorUnited States
-
Duke UniversityMonteris MedicalWithdrawnGlioblastoma | Malignant Glioma of BrainUnited States
-
Children's Hospitals and Clinics of MinnesotaCompletedBrain TumorUnited States
-
University of FloridaMonteris MedicalTerminatedMelanoma | Primary Mediastinal Large B-Cell Lymphoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Cancer | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Brain Metastases, Adult | Renal Cell... and other conditionsUnited States
-
Monteris MedicalTerminated
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingMalignant GliomaUnited States
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil